Cargando…

The Multi-Biomarker Approach for Heart Failure in Patients with Hypertension

We assessed the predictive ability of selected biomarkers using N-terminal pro-brain natriuretic peptide (NT-proBNP) as the benchmark and tried to establish a multi-biomarker approach to heart failure (HF) in hypertensive patients. In 120 hypertensive patients with or without overt heart failure, th...

Descripción completa

Detalles Bibliográficos
Autores principales: Bielecka-Dabrowa, Agata, Gluba-Brzózka, Anna, Michalska-Kasiczak, Marta, Misztal, Małgorzata, Rysz, Jacek, Banach, Maciej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4463672/
https://www.ncbi.nlm.nih.gov/pubmed/25984599
http://dx.doi.org/10.3390/ijms160510715
_version_ 1782375813715329024
author Bielecka-Dabrowa, Agata
Gluba-Brzózka, Anna
Michalska-Kasiczak, Marta
Misztal, Małgorzata
Rysz, Jacek
Banach, Maciej
author_facet Bielecka-Dabrowa, Agata
Gluba-Brzózka, Anna
Michalska-Kasiczak, Marta
Misztal, Małgorzata
Rysz, Jacek
Banach, Maciej
author_sort Bielecka-Dabrowa, Agata
collection PubMed
description We assessed the predictive ability of selected biomarkers using N-terminal pro-brain natriuretic peptide (NT-proBNP) as the benchmark and tried to establish a multi-biomarker approach to heart failure (HF) in hypertensive patients. In 120 hypertensive patients with or without overt heart failure, the incremental predictive value of the following biomarkers was investigated: Collagen III N-terminal propeptide (PIIINP), cystatin C (CysC), lipocalin-2/NGAL, syndecan-4, tumor necrosis factor-α (TNF-α), interleukin 1 receptor type I (IL1R1), galectin-3, cardiotrophin-1 (CT-1), transforming growth factor β (TGF-β) and N-terminal pro-brain natriuretic peptide (NT-proBNP). The highest discriminative value for HF was observed for NT-proBNP (area under the receiver operating characteristic curve (AUC) = 0.873) and TGF-β (AUC = 0.878). On the basis of ROC curve analysis we found that CT-1 > 152 pg/mL, TGF-β < 7.7 ng/mL, syndecan > 2.3 ng/mL, NT-proBNP > 332.5 pg/mL, CysC > 1 mg/L and NGAL > 39.9 ng/mL were significant predictors of overt HF. There was only a small improvement in predictive ability of the multi-biomarker panel including the four biomarkers with the best performance in the detection of HF—NT-proBNP, TGF-β, CT-1, CysC—compared to the panel with NT-proBNP, TGF-β and CT-1 only. Biomarkers with different pathophysiological backgrounds (NT-proBNP, TGF-β, CT-1, CysC) give additive prognostic value for incident HF in hypertensive patients compared to NT-proBNP alone.
format Online
Article
Text
id pubmed-4463672
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-44636722015-06-16 The Multi-Biomarker Approach for Heart Failure in Patients with Hypertension Bielecka-Dabrowa, Agata Gluba-Brzózka, Anna Michalska-Kasiczak, Marta Misztal, Małgorzata Rysz, Jacek Banach, Maciej Int J Mol Sci Article We assessed the predictive ability of selected biomarkers using N-terminal pro-brain natriuretic peptide (NT-proBNP) as the benchmark and tried to establish a multi-biomarker approach to heart failure (HF) in hypertensive patients. In 120 hypertensive patients with or without overt heart failure, the incremental predictive value of the following biomarkers was investigated: Collagen III N-terminal propeptide (PIIINP), cystatin C (CysC), lipocalin-2/NGAL, syndecan-4, tumor necrosis factor-α (TNF-α), interleukin 1 receptor type I (IL1R1), galectin-3, cardiotrophin-1 (CT-1), transforming growth factor β (TGF-β) and N-terminal pro-brain natriuretic peptide (NT-proBNP). The highest discriminative value for HF was observed for NT-proBNP (area under the receiver operating characteristic curve (AUC) = 0.873) and TGF-β (AUC = 0.878). On the basis of ROC curve analysis we found that CT-1 > 152 pg/mL, TGF-β < 7.7 ng/mL, syndecan > 2.3 ng/mL, NT-proBNP > 332.5 pg/mL, CysC > 1 mg/L and NGAL > 39.9 ng/mL were significant predictors of overt HF. There was only a small improvement in predictive ability of the multi-biomarker panel including the four biomarkers with the best performance in the detection of HF—NT-proBNP, TGF-β, CT-1, CysC—compared to the panel with NT-proBNP, TGF-β and CT-1 only. Biomarkers with different pathophysiological backgrounds (NT-proBNP, TGF-β, CT-1, CysC) give additive prognostic value for incident HF in hypertensive patients compared to NT-proBNP alone. MDPI 2015-05-12 /pmc/articles/PMC4463672/ /pubmed/25984599 http://dx.doi.org/10.3390/ijms160510715 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bielecka-Dabrowa, Agata
Gluba-Brzózka, Anna
Michalska-Kasiczak, Marta
Misztal, Małgorzata
Rysz, Jacek
Banach, Maciej
The Multi-Biomarker Approach for Heart Failure in Patients with Hypertension
title The Multi-Biomarker Approach for Heart Failure in Patients with Hypertension
title_full The Multi-Biomarker Approach for Heart Failure in Patients with Hypertension
title_fullStr The Multi-Biomarker Approach for Heart Failure in Patients with Hypertension
title_full_unstemmed The Multi-Biomarker Approach for Heart Failure in Patients with Hypertension
title_short The Multi-Biomarker Approach for Heart Failure in Patients with Hypertension
title_sort multi-biomarker approach for heart failure in patients with hypertension
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4463672/
https://www.ncbi.nlm.nih.gov/pubmed/25984599
http://dx.doi.org/10.3390/ijms160510715
work_keys_str_mv AT bieleckadabrowaagata themultibiomarkerapproachforheartfailureinpatientswithhypertension
AT glubabrzozkaanna themultibiomarkerapproachforheartfailureinpatientswithhypertension
AT michalskakasiczakmarta themultibiomarkerapproachforheartfailureinpatientswithhypertension
AT misztalmałgorzata themultibiomarkerapproachforheartfailureinpatientswithhypertension
AT ryszjacek themultibiomarkerapproachforheartfailureinpatientswithhypertension
AT banachmaciej themultibiomarkerapproachforheartfailureinpatientswithhypertension
AT bieleckadabrowaagata multibiomarkerapproachforheartfailureinpatientswithhypertension
AT glubabrzozkaanna multibiomarkerapproachforheartfailureinpatientswithhypertension
AT michalskakasiczakmarta multibiomarkerapproachforheartfailureinpatientswithhypertension
AT misztalmałgorzata multibiomarkerapproachforheartfailureinpatientswithhypertension
AT ryszjacek multibiomarkerapproachforheartfailureinpatientswithhypertension
AT banachmaciej multibiomarkerapproachforheartfailureinpatientswithhypertension